Aceso Life Science Group (474.HK) Stock Price

Aceso Life Science Group Price

🇭🇰CLOSED
0 HKD
Market closed
Today +/-
Today %

Aceso Life Science Group (474.HK) Stock | ISIN KYG0070S1066. Aceso Life Science Group operates in the Finance sector.

Aceso Life Science Group stock price

Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Aceso Life Science Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Aceso Life Science Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Aceso Life Science Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Aceso Life Science Group Stock Price History
DateAceso Life Science Group Price
Access this data via the Eulerpool API
Get Free API Key

Aceso Life Science Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
151.1 M HKD
23.2 M HKD
26.8 M HKD
Jan 1, 2007
156.5 M HKD
28.2 M HKD
28.1 M HKD
Jan 1, 2008
176.8 M HKD
21.8 M HKD
22.2 M HKD
Jan 1, 2009
166.5 M HKD
7.8 M HKD
-22.9 M HKD
Jan 1, 2010
97 M HKD
-19.1 M HKD
-469.4 M HKD
Jan 1, 2011
122.1 M HKD
-47.8 M HKD
-96.6 M HKD
Jan 1, 2012
140.2 M HKD
-48.1 M HKD
-378.5 M HKD
Jan 1, 2013
0 HKD
-59.9 M HKD
-219.3 M HKD
Jan 1, 2014
40.3 M HKD
-35.1 M HKD
-12.4 M HKD
Jan 1, 2015
60.9 M HKD
-7.32 M HKD
1.52 B HKD
Jan 1, 2016
129.99 M HKD
41.86 M HKD
524.4 M HKD
Jan 1, 2017
206.31 M HKD
2.81 M HKD
-3.08 B HKD
Jan 1, 2018
330.02 M HKD
-69.99 M HKD
-444.91 M HKD
Jan 1, 2019
319.51 M HKD
-16 M HKD
-380.87 M HKD
Jan 1, 2020
295.65 M HKD
75.27 M HKD
-283.72 M HKD

Aceso Life Science Group Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 12, 2026, 10:19 AM
 
REVENUE (M HKD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M HKD)
NET INCOME (B HKD)
NET INCOME GROWTH (%)
SHARES (B)
DOCUMENTS
20182019202020212022202320242025
330319295346315312228195
60.19-3.33-7.5217.29-8.96-0.95-26.92-14.47
43.9447.9656.2761.5651.4345.1951.3246.15
14515316621316214111790
-0.44-0.38-0.28-0.38-0.37-0.26-0.46-0.9
-85.58-14.41-25.5332.86-1.6-28.657593.72
4.884.945.786.567.27.327.277.2
––––––––
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Aceso Life Science Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Aceso Life Science Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Aceso Life Science Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Aceso Life Science Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Aceso Life Science Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Aceso Life Science Group stock margins

The Aceso Life Science Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aceso Life Science Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aceso Life Science Group.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
38.25 %
15.35 %
17.74 %
Jan 1, 2007
36.87 %
18.02 %
17.96 %
Jan 1, 2008
31.45 %
12.33 %
12.56 %
Jan 1, 2009
22.76 %
4.68 %
-13.75 %
Jan 1, 2010
11.75 %
-19.69 %
-483.92 %
Jan 1, 2011
15.56 %
-39.15 %
-79.12 %
Jan 1, 2012
25.18 %
-34.31 %
-269.97 %
Jan 1, 2013
46.15 %
- %
- %
Jan 1, 2014
46.15 %
-87.1 %
-30.77 %
Jan 1, 2015
46.15 %
-12.01 %
2,500.15 %
Jan 1, 2016
46.15 %
32.2 %
403.43 %
Jan 1, 2017
82.2 %
1.36 %
-1,492.34 %
Jan 1, 2018
44.16 %
-21.21 %
-134.81 %
Jan 1, 2019
47.99 %
-5.01 %
-119.2 %
Jan 1, 2020
56.35 %
25.46 %
-95.97 %

Aceso Life Science Group Stock Revenue, EBIT, Earnings per Share

The Aceso Life Science Group earnings per share therefore indicates how much revenue Aceso Life Science Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2006
0.71 HKD
0.11 HKD
0.13 HKD
Jan 1, 2007
0.73 HKD
0.13 HKD
0.13 HKD
Jan 1, 2008
0.8 HKD
0.1 HKD
0.1 HKD
Jan 1, 2009
0.76 HKD
0.04 HKD
-0.1 HKD
Jan 1, 2010
0.29 HKD
-0.06 HKD
-1.4 HKD
Jan 1, 2011
0.11 HKD
-0.04 HKD
-0.09 HKD
Jan 1, 2012
0.09 HKD
-0.03 HKD
-0.24 HKD
Jan 1, 2013
0 HKD
-0.03 HKD
-0.1 HKD
Jan 1, 2014
0.02 HKD
-0.02 HKD
-0.01 HKD
Jan 1, 2015
0.02 HKD
-0 HKD
0.53 HKD
Jan 1, 2016
0.03 HKD
0.01 HKD
0.13 HKD
Jan 1, 2017
0.04 HKD
0 HKD
-0.64 HKD
Jan 1, 2018
0.07 HKD
-0.01 HKD
-0.09 HKD
Jan 1, 2019
0.06 HKD
-0 HKD
-0.08 HKD
Jan 1, 2020
0.05 HKD
0.01 HKD
-0.05 HKD

Aceso Life Science Group business model & stock analysis

Aceso Life Science Group Ltd is a UK-based company specializing in the field of medical cannabis. The company was founded in 2016 when the founders recognized the growing demand for medical cannabis and decided to utilize their expertise in this area to establish a company focused on the development and marketing of cannabis products. Aceso's business model is based on various pillars. On one hand, the company offers product design and research and development in the field of medical cannabis products. Aceso also provides various services to help other companies and research institutions develop and bring their own commercial products to market. The company also has a strong presence in retail, where it offers a wide range of cannabinoid products. Aceso Life Science Group has various divisions that focus on the production of medical cannabis products. This includes the manufacturing of medical cannabinoids, which involves the preparation of cannabis oil and other products. Aceso also offers various types of medical cannabis, such as different THC and CBD-based products, and has also developed a special line of products targeting women. Aceso also has a strong presence in research and development, with a dedicated department focused on the development of new and improved cannabinoid products. Aceso's research department works closely with academic research institutions and other organizations to investigate and improve the efficacy and safety of medical cannabis and its derivatives. The products offered by Aceso primarily include medical oils, capsules, tinctures, and creams. These products contain a wide range of cannabinoids, such as CBD, THC, CBG, and CBN, which can be used to treat various conditions. Aceso has also developed a special series of products targeting women, including specific vaginal creams that can be used to treat pain and discomfort associated with the menstrual cycle and other conditions. Overall, Aceso Life Science Group Ltd has established itself as a leading company in the field of medical cannabis products. The company has developed a wide range of products and services aimed at providing its customers with a safe and effective way to treat various conditions. With a strong retail presence and a dedicated research department, Aceso has everything it needs to continue to play a pioneering role in the medical cannabis industry.

Aceso Life Science Group SWOT Analysis

Strengths

Aceso Life Science Group Ltd possesses several key strengths that contribute to its success in the industry. Firstly, the company has a strong reputation for providing high-quality products and services to its customers. This has resulted in a loyal customer base and positive word-of-mouth referrals, which further enhances the company's brand image and market position. Additionally, Aceso Life Science Group Ltd benefits from a team of experienced professionals who possess deep knowledge and expertise in the field. This enables the company to develop innovative solutions and stay ahead of competitors. Furthermore, the company enjoys strong financial stability, enabling it to invest in research and development and expand its operations.

Weaknesses

Despite its strengths, Aceso Life Science Group Ltd also faces certain weaknesses that need to be addressed. One of the main weaknesses is its limited geographic presence. The company primarily operates in a specific region, which may restrict its growth potential in other markets. Another weakness is the reliance on a small number of key customers. This presents a risk as the loss of a major customer could have a significant impact on the company's revenue. Additionally, the company may face challenges in scaling its operations due to potential resource constraints or inefficient processes.

Opportunities

Aceso Life Science Group Ltd has several opportunities to capitalize on in the evolving market. Firstly, there is a growing demand for innovative healthcare solutions globally. The company can leverage its expertise and reputation to expand its product offerings and enter new markets. Moreover, there is an increasing focus on personalized medicine and preventive healthcare, presenting opportunities for Aceso Life Science Group Ltd to develop customized solutions to cater to this demand. Additionally, strategic partnerships and collaborations with other industry players can help the company access new markets, share resources, and enhance its competitive position.

Threats

Despite its potential, Aceso Life Science Group Ltd faces several threats that could impact its success. Firstly, the healthcare industry is highly regulated, and changes in regulations or compliance requirements can pose challenges for the company. Moreover, the entry of new competitors with disruptive technologies or lower-priced alternatives could erode Aceso Life Science Group Ltd's market share. Additionally, fluctuations in the global economy or changes in consumer behavior can impact the demand for healthcare products and services. Finally, emerging technologies and advancements in medical research may render existing solutions obsolete, requiring the company to constantly innovate and adapt.

Aceso Life Science Group Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Aceso Life Science Group historical P/E ratio, EBIT multiple, and P/S ratio

Aceso Life Science Group annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Aceso Life Science Group shares outstanding

The number of shares was Aceso Life Science Group in 2025 — This indicates how many shares 7.197 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2006
213.7 M base_Shares
Jan 1, 2007
213.7 M base_Shares
Jan 1, 2008
220.7 M base_Shares
Jan 1, 2009
219.2 M base_Shares
Jan 1, 2010
336 M base_Shares
Jan 1, 2011
1.08 B base_Shares
Jan 1, 2012
1.56 B base_Shares
Jan 1, 2013
2.1 B base_Shares
Jan 1, 2014
2.12 B base_Shares
Jan 1, 2015
2.85 B base_Shares
Jan 1, 2016
4.14 B base_Shares
Jan 1, 2017
4.82 B base_Shares
Jan 1, 2018
4.88 B base_Shares
Jan 1, 2019
4.94 B base_Shares
Jan 1, 2020
5.78 B base_Shares

Aceso Life Science Group Dividend History

5 years of dividend payments

YearAnnual DividendYoY ChangePayments
20100.09HKD↑ 679.2%—
20090.01HKD↓ 52.0%1×
20080.03HKD 0.0%1×
20070.03HKD 0.0%1×
20060.03HKD—1×

Aceso Life Science Group dividend payout ratio

In 2025, Aceso Life Science Group had a payout ratio of 172.32%. The payout ratio indicates the percentage of the company's profits that Aceso Life Science Group distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2006
149.85 %
Jan 1, 2007
149.85 %
Jan 1, 2008
194.8 %
Jan 1, 2009
-93.5 %
Jan 1, 2010
164.83 %
Jan 1, 2011
169.83 %
Jan 1, 2012
176.49 %
Jan 1, 2013
170.38 %
Jan 1, 2014
172.23 %
Jan 1, 2015
173.03 %
Jan 1, 2016
171.88 %
Jan 1, 2017
172.38 %
Jan 1, 2018
172.43 %
Jan 1, 2019
172.23 %
Jan 1, 2020
172.35 %
Price targets and forecasts for Aceso Life Science Group are not yet available.

Aceso Life Science Group shareholder structure

% Name
57.25557%
Li (Shao Yu)
Li (Shao Yu)
20.51341%
Imagi Brokerage Limited
Imagi Brokerage Limited
11.11574%
Century Golden Resources Investment Co., Ltd.
Century Golden Resources Investment Co., Ltd.
5.59675%
Glory Century Ltd
Glory Century Ltd
0.84579%
Fok (Chi Tak CPA)
Fok (Chi Tak CPA)
0.0102%
Chan (Ming Sun)
Chan (Ming Sun)
0.0102%
Ou (Zhiliang)
Ou (Zhiliang)
0.0102%
Lam (Kwan Sing)
Lam (Kwan Sing)
0.00281%
DFA Australia Ltd.
DFA Australia Ltd.
%
Dimensional Fund Advisors, Ltd.
Dimensional Fund Advisors, Ltd.

Aceso Life Science Group Executives and Management Board

CF

Mr. Chi Tak Fok

(46)

Chief Financial Officer, Executive Director · since 2010

Compensation7.8 M HKD
ZO

Dr. Zhiliang Ou

(53)

Executive Director · since 2012

Compensation600,000 HKD
MC

Mr. Ming Sun Chan

(49)

Independent Non-Executive Director

Compensation200,000 HKD
KL

Mr. Kwan Sing Lam

(53)

Independent Non-Executive Director

Compensation200,000 HKD
YM

Mr. Yiu Tong Mak

(63)

Non-Executive Independent Director · since 2010

Compensation100,000 HKD

Aceso Life Science Group Supply Chain

Frequently asked questions about Aceso Life Science Group

Aceso Life Science Group Ltd is a company that operates in the life sciences industry. The business model of Aceso Life Science Group Ltd is focused on providing innovative healthcare solutions and services. They aim to improve patient outcomes and deliver cost-effective healthcare solutions through advanced technologies and research. With a strong emphasis on research and development, Aceso Life Science Group Ltd strives to create and commercialize new medical devices, pharmaceuticals, and therapies. By combining their expertise in life sciences and cutting-edge technology, Aceso Life Science Group Ltd aims to drive advancements in healthcare and contribute to the well-being of patients worldwide.

All fundamentals and in-depth analysis of Aceso Life Science Group

Our stock analysis for Aceso Life Science Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aceso Life Science Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Aceso Life Science Group Stock
Aceso Life Science Group Revenue→
Aceso Life Science Group Stock
Aceso Life Science Group Net Income→
Aceso Life Science Group Stock
Aceso Life Science Group P/E→
Aceso Life Science Group Stock
Aceso Life Science Group P/S→
Aceso Life Science Group Stock
Aceso Life Science Group EBIT→
Aceso Life Science Group Stock
Aceso Life Science Group Dividend→
Aceso Life Science Group Stock
Aceso Life Science Group Directors Dealings→
Aceso Life Science Group Stock
Aceso Life Science Group Stocks→
Aceso Life Science Group Stock
Aceso Life Science Group Market capitalization→
Aceso Life Science Group Stock
Aceso Life Science Group Debt→
Aceso Life Science Group Stock
Aceso Life Science Group Liabilities→
Aceso Life Science Group Stock
Aceso Life Science Group Equity→
Aceso Life Science Group Stock
Aceso Life Science Group AAQS→
Aceso Life Science Group Stock
Aceso Life Science Group Employees→
Aceso Life Science Group Stock
Aceso Life Science Group ROE→
Aceso Life Science Group Stock
Aceso Life Science Group ROA→
Aceso Life Science Group Stock
Aceso Life Science Group ROCE→